The European Investment Bank (EIB) and CureVac, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimised mRNA, entered into a €75 million loan agreement to support the Company’s ongoing development of vaccines against infectious diseases, including its vaccine candidate CVnCoV aimed at preventing SARS-CoV-2 infections. El préstamo, además, apoyará los […]
European Commission unveils EU vaccines strategy
The European Commission has presented a European strategy to accelerate the development, manufacture and deployment of vaccines against COVID-19. An effective and safe vaccine against the virus is our best bet for a permanent solution to the pandemic. The Commission will support efforts to accelerate the development and availability of safe and effective vaccines within […]
H2020. Innovations to accelerate vaccine development and manufacture
Vaccination is one of the greatest achievements in healthcare. However, developing a vaccine remains costly, time-consuming, and risky. Advances in immunology, disease modelling, in silico modelling, including the analysis of big data and the application of machine learning (ML) artificial intelligence (AI), provide opportunities to innovate, de-risk and accelerate the vaccine-development process. Many of these […]
Global regulators map out data requirements for phase 1 COVID-19 vaccine trials
Global regulators have published a report presenting the outcomes of a workshop on COVID-19 vaccine development that was convened under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA). The meeting report provides an overview of regulatory considerations related to COVID-19 vaccine development and data required for regulatory decision-making on two key points: Pre-clinical data […]
First vaccine to protect against Ebola
EMA’s human medicines committee (CHMP) has recommended granting a conditional marketing authorisation in the European Union for Ervebo (rVSVΔG-ZEBOV-GP), the first vaccine for active immunisation of individuals aged 18 years and older at risk of infection with the Ebola virus. “The CHMP’s recommendation is the result of many years of collaborative global efforts to find and develop new medicines […]